entertainment -WSS

entertainment

author：fashion 2025-09-06 03:55:08 - browse：6

Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT — Molly Ferguson for STAT

The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

WSS

Startling documents reveal new facets of Sacklers' opioid empire

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Hospitals owned by private equity see complications spike 25%

Grail spinoff by Illumina should end disastrous merger attempt

Akili, maker of video game for ADHD, to be acquired for 34 million

knowledge

entertainment

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Albert Bourla of Pfizer: worst biopharma CEO of 2023

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Average age of first period drops to 11.9 years, study shows

Psychedelics group wrestles with new pharma identity

Keeping primary care docs in field isn't impossible, says AAFP CEO

ChatGPT in medicine: STAT answers readers' burning questions

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Heart attack and stroke risk calculators need revising

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

knowledge

Latest bird flu infection made farmworker sicker than earlier cases

Keeping primary care docs in field isn't impossible, says AAFP CEO

Medicare Advantage beneficiaries sue Humana over algorithm use

iTeos Therapeutics debuts first data on TIGIT

HCA sued by state AG for quality issues at Mission Health

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

leisure time

hotspot

leisure time

Wikipedia